Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Dr. Adrian ...

The first patient has been dosed in a Phase 1 trial testing the experimental CAR T-cell therapy obecabtagene autoleucel for progressive MS.

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the ...

Allogene Therapeutics, Inc. downgraded to Hold after ALPHA3 trial setbacks. Review updated pipeline prospects and risks.

Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I(TM)), today announced an evaluation and license agreement with Umoja Biopharma ("Umoja"), the ...

CD19-directed CAR T-cell therapy can lead to sustained remission in DLBCL, but relapse is common, affecting up to 60% of patients. Epcoritamab, a bispecific T-cell engager, may enhance CAR T-cell ...

Discover how CAR T cell therapy is breaking new ground in treating Multiple Sclerosis for the first time in the UK ...

This report, published by Towards Healthcare, a sister firm of Precedence Research, provides an in-depth analysis of the CAR T-cell neurotoxicity detection market. It explores key growth drivers, ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...

The global car t-cell therapy market size is predicted to increase from USD 7.64 billion in 2025 and is anticipated to be ...